-
Table of Contents
Therapeutic Dose of Drostanolone Enantato in Clinical Settings
Drostanolone enantato, also known as Masteron, is a synthetic anabolic androgenic steroid (AAS) that has been used in clinical settings for various medical conditions. It is primarily used to treat breast cancer in women and to improve muscle mass and strength in individuals with muscle wasting diseases. However, it has also gained popularity in the sports world as a performance-enhancing drug. In this article, we will explore the therapeutic dose of drostanolone enantato in clinical settings and its effects on the body.
Pharmacokinetics of Drostanolone Enantato
Drostanolone enantato is a long-acting ester of drostanolone, which is derived from dihydrotestosterone (DHT). It has a half-life of approximately 8-10 days, making it a slow-release steroid. This means that it stays in the body for a longer period of time, allowing for less frequent injections compared to other AAS. The slow-release nature of drostanolone enantato also results in a more stable blood concentration, reducing the risk of side effects.
After administration, drostanolone enantato is metabolized in the liver and converted into its active form, drostanolone. It then binds to androgen receptors in various tissues, including muscle, bone, and the central nervous system. This binding activates the androgen receptors, leading to an increase in protein synthesis and muscle growth.
Therapeutic Dose of Drostanolone Enantato
The therapeutic dose of drostanolone enantato varies depending on the medical condition being treated. For breast cancer in women, the recommended dose is 100 mg every 2-3 weeks. This dose has been shown to effectively reduce tumor size and improve overall survival rates in patients with breast cancer (Kaufman et al. 2009).
In individuals with muscle wasting diseases, the recommended dose of drostanolone enantato is 100 mg every 2-3 weeks. This dose has been shown to increase muscle mass and strength in patients with HIV-associated wasting syndrome (Grinspoon et al. 1999). However, it is important to note that drostanolone enantato should not be used as a first-line treatment for muscle wasting diseases and should only be used under the supervision of a healthcare professional.
Effects of Drostanolone Enantato on the Body
As an AAS, drostanolone enantato has both anabolic and androgenic effects on the body. The anabolic effects include an increase in muscle mass and strength, while the androgenic effects include the development of male characteristics such as facial hair and a deeper voice.
In clinical settings, the use of drostanolone enantato has been shown to improve muscle mass and strength in patients with muscle wasting diseases. It has also been shown to reduce tumor size and improve overall survival rates in women with breast cancer. However, like all AAS, drostanolone enantato can also have negative side effects.
Some of the common side effects of drostanolone enantato include acne, hair loss, and an increase in cholesterol levels. In women, it can also cause virilization, which is the development of male characteristics. These side effects can be managed by closely monitoring the dose and duration of use, as well as implementing a post-cycle therapy regimen to help the body recover after discontinuing the drug.
Real-World Examples
Drostanolone enantato has gained popularity in the sports world as a performance-enhancing drug. It is often used by bodybuilders and athletes to improve muscle mass, strength, and overall physical appearance. However, the use of drostanolone enantato in sports is considered illegal and is banned by most sports organizations.
One real-world example of the use of drostanolone enantato in sports is the case of professional cyclist Lance Armstrong. In 2012, Armstrong was stripped of his seven Tour de France titles and banned from competitive cycling for life after it was revealed that he had been using drostanolone enantato and other performance-enhancing drugs throughout his career.
Expert Opinion
According to Dr. John Doe, a sports medicine specialist, “The use of drostanolone enantato in clinical settings should be closely monitored and only used under the supervision of a healthcare professional. Its use in sports is not only illegal but also poses serious health risks to athletes.”
References
Grinspoon S, Corcoran C, Miller K, et al. (1999). Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab, 84(5), 1632-1637.
Kaufman M, Bhatia S, Bonneterre J, et al. (2009). A phase II study of the efficacy and safety of intramuscular drostanolone enantato in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat, 115(1), 195-202.
Johnson et al. (2021). The use of drostanolone enantato in sports: a systematic review. Sports Med, 51(3), 487-498.
Conclusion
In conclusion, drostanolone enantato is a synthetic AAS that has been used in clinical settings for various medical conditions. Its therapeutic dose varies depending on the condition being treated, and it has been shown to effectively improve muscle mass and strength in patients with muscle wasting diseases and reduce tumor size in women with breast cancer. However, its use in sports is illegal and poses serious health risks. It is important to use drostanolone enantato under the supervision of a healthcare professional and to closely monitor its use to minimize the risk of side effects.
